[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jiangsu Province Nanjing Brain Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":289},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,72,98,127,149,177,207,233,263],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100629872","tis-for-brain-network-modulation-and-clinical-efficacy-in-parkinsons-disease-100629872",false,"NCT07480317","TIS for Brain Network Modulation and Clinical Efficacy in Parkinson's Disease","Mechanism of Temporal Interference Stimulation on Brain Networks and Its Long-term Clinical Efficacy in Parkinson's Disease","PD TIS","Inclusion Criteria:\n\n* Diagnosed with Parkinson's Disease according to the Movement Disorder Society (MDS) clinical diagnostic criteria.\n* Hoehn \\& Yahr Stage I-III (mild to moderate severity).\n* Aged 45 to 65 years.\n* Right-handed. Stable medication regimen for at least 1 hour before Phase A fMRI sessions and agreement to maintain a stable dosage during the 2-week Phase B intervention (unless clinically necessary).\n* Able to provide informed consent by the participant or a legal guardian.\n\nExclusion Criteria:\n\n* MRI contraindications, such as implanted DBS electrodes, cardiac pacemakers, or other metal implants.\n* Significant cognitive impairment (MoCA score \\\u003C 24) or severe psychiatric symptoms.\n* History of epilepsy or structural brain lesions, including severe cerebral atrophy or cerebrovascular disease.\n* Severe head tremors that would interfere with MRI scanning quality.","ALL","45 Years","65 Years",{"count":21,"type":22},75,"ESTIMATED","INTERVENTIONAL",[25],"NA","Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor dysfunction. While deep brain stimulation (DBS) is effective, its invasive nature limits its application in early-stage patients. Temporal interference stimulation (TIS) is a novel non-invasive technique that can target deep brain structures like the globus pallidus internus (GPi) by using high-frequency electric fields.\n\nThis study aims to evaluate the clinical value and underlying mechanisms of TIS in PD patients. The research is divided into two phases: Phase A investigates the immediate regulatory effects of 130 Hz and 40 Hz TIS on brain networks using concurrent fMRI-TIS. Phase B is a randomized, double-blind, sham-controlled trial to assess the long-term efficacy and safety of a 2-week TIS intervention on both motor and non-motor symptoms. The results will help clarify how TIS modulates deep brain networks and its potential as a non-invasive therapy for PD.",[28],"PARKINSON DISEASE (Disorder)",[30,31,32,33],"Temporal Interference Stimulation (TIS)","Functional Magnetic Resonance Imaging (fMRI)","Non-invasive Brain Stimulation (NIBS)","Neuromodulation","NOT_YET_RECRUITING","2026-03-20",{"date":37,"type":38},"2026-03-24","ACTUAL",{"date":35,"type":22},{"date":41,"type":22},"2027-03-31",{"name":43,"class":44},"Jiangsu Province Nanjing Brain Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100630807","the-effects-of-low-intensity-music-in-adolescents-with-anxiety-100630807","NCT07492472","The Effects of Low-Intensity Music in Adolescents With Anxiety","The Effects of Low-Intensity Music on Brain-Heart Function in Adolescents With Anxiety","Inclusion Criteria:\n\n* Participants experiencing anxiety episodes were adolescents aged 18-25 years with a Generalized Anxiety Disorder-7 (GAD-7) score ≥ 5;\n* Participants completed self-report symptom assessments via a digital mental health screening platform, alongside the collection of acoustic voice features, heart rate, and functional near-infrared spectroscopy (fNIRS) data;\n* All participants were required to provide written informed consent;\n\nExclusion Criteria:\n\n* History of major somatic illnesses, particularly those potentially associated with brain tissue alterations, such as hypertension, diabetes, or metastatic tumors; unstable physical conditions, including severe asthma; and a history of neurological abnormalities, including significant head trauma (loss of consciousness lasting more than five minutes), epilepsy, cerebrovascular disease, brain tumors, and neurodegenerative disorders;\n* Somatic conditions that may induce mood disorder symptoms, such as multiple sclerosis or thyroid disorders;\n* IQ below 70;\n* Autism spectrum disorder (ASD) or pervasive developmental disorder (PDD);\n* Participants with significant substance abuse or dependence within the three months preceding enrollment were excluded;\n* Participants at high risk for suicide or with a prior history of suicide attempts were excluded;","18 Years","25 Years",{"count":56,"type":22},60,[25],"In modern society, increasing attention has been devoted to mental health problems among adolescents, with anxiety and depressive disorders being particularly prevalent in this population. Evidence indicates that anxiety not only affects emotional states and daily quality of life but also has significant impacts on physiological health, including blood pressure and heart rate. At present, clinical treatment relies primarily on pharmacological interventions and cognitive behavioral therapy; however, these approaches are associated with limitations such as pronounced side effects and delayed onset of efficacy, which restrict their applicability in adolescents. Music and other structured sounds have been used since ancient times to alleviate negative emotional states such as tension and anxiety. Research has shown that listening to soothing music can reduce sympathetic nervous system activity while enhancing parasympathetic tone, thereby leading to a decrease in heart rate and an increase in heart rate variability (HRV). Owing to its gentle characteristics, low-intensity soothing music is considered effective in relieving stress, regulating emotional states, and exerting beneficial effects on physiological indicators.",[60],"Anxiety",[62],"Music Therapy","RECRUITING","2026-03-19",{"date":66,"type":38},"2026-03-25",{"date":68,"type":38},"2025-12-15",{"date":70,"type":22},"2026-12-31",{"name":43,"class":44},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":97,"locationsCount":45},"100617356","remote-ischemic-conditioning-for-cognitive-impairment-in-cerebral-small-vessel-disease-100617356","NCT07317557","Remote Ischemic Conditioning for Cognitive Impairment in Cerebral Small Vessel Disease","Mechanisms of Remote Ischemic Conditioning in Preventing and Treating Cognitive Impairment in Cerebral Small Vessel Disease","RIC-CSVD","Inclusion Criteria:\n\n* Age 30-80 years.\n* Diagnosis of cerebral small vessel disease according to the Chinese Guidelines for the Diagnosis and Treatment of Cerebral Small Vessel Disease (2020).\n* Mild cognitive impairment with a Montreal Cognitive Assessment (MoCA) score of 18-25.\n* The patient or a legally authorized representative is able and willing to sign written informed consent.\n\nExclusion Criteria:\n\n* Any condition that is unsuitable for remote ischemic conditioning, including soft tissue injury, limb deformity or vascular injury in the upper limb, bleeding disorders, or systolic blood pressure \\> 200 mmHg.\n* History or presence of neurological or psychiatric disorders that may interfere with participation or outcome assessment, such as other cerebrovascular diseases, Parkinson's disease, or major depressive disorder.\n* Current or past severe systemic diseases deemed inappropriate for the study by the investigator, including but not limited to severe cardiovascular diseases (e.g., congestive heart failure, severe arrhythmia, myocardial infarction), severe hepatic diseases (e.g., cirrhosis), severe renal diseases (e.g., requiring hemodialysis or peritoneal dialysis), hematologic diseases with bleeding tendency (e.g., hemophilia), poorly controlled diabetes (blood glucose \\> 16.8 mmol\u002FL or \\\u003C 2.8 mmol\u002FL) or with severe complications, active or uncontrolled systemic autoimmune diseases or primary\u002Fsecondary immunodeficiency, or malignancy.\n* Laboratory abnormalities, including absolute neutrophil count \\\u003C 1.5 × 10⁹\u002FL, platelet count \\\u003C 100 × 10⁹\u002FL, hemoglobin \\\u003C 90 g\u002FL, AST or ALT \\> 2.5 × upper limit of normal (ULN), total bilirubin \\> 1.5 × ULN, or serum creatinine \\> 1.5 × ULN.\n* Coagulation abnormalities, including for patients not on anticoagulant\u002Fantithrombotic therapy: INR \\> 1.7 or APTT \\> 1.25 × ULN; and for patients on anticoagulant\u002Fantithrombotic therapy: INR \\> 3.0 or APTT \\> 1.5 × ULN.\n* Positive tests for hepatitis B with detectable HBV-DNA, or positive serology for hepatitis C, syphilis (TPAb\u002FRPR), or HIV.\n* Pregnant or breastfeeding women.\n* Contraindications to MRI (e.g., pacemaker or other metallic implants, severe claustrophobia).\n* Participation in another clinical trial within 3 months prior to enrollment.\n* Severe trauma or major surgery within 3 months before remote ischemic conditioning, or planned surgery during the study period (except minor procedures and laparoscopic procedures performed within 4 weeks before baseline).\n* History of substance abuse or alcoholism within 1 year prior to enrollment.\n* Any other condition that may increase risk or interfere with the interpretation of study results, as judged by the investigator.","30 Years","80 Years",{"count":83,"type":22},40,[25],"This randomized, double-blind, sham-controlled trial aims to evaluate the effect of remote ischemic conditioning (RIC) on cognitive function in patients with cerebral small vessel disease-related mild cognitive impairment. Forty eligible participants will be randomized 1:1 to receive either RIC or sham RIC twice daily for 90 days in addition to standard medical therapy. The primary outcome is the change in Montreal Cognitive Assessment (MoCA) score from baseline to 90 days. Secondary outcomes include changes in white matter hyperintensity burden and diffusion tensor imaging metrics on MRI, EEG functional connectivity, and activities of daily living.",[87,88],"Cerebral Small Vessel Disease","Cognitive Impairment",[90],"cerebral small vessel disease; cognitive impairment; remote ischemic conditioning; white matter hyperintensities; EEG functional connectivity","2026-03-06",{"date":93,"type":38},"2026-03-10",{"date":95,"type":22},"2026-04-01",{"date":70,"type":22},{"name":43,"class":44},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":126,"locationsCount":4},"100617784","40-hz-flickering-for-insomnia-in-parkinsons-disease-100617784","NCT07323121","40 Hz Flickering for Insomnia in Parkinson's Disease","Randomized, Single-blind, Controlled Study of 40 Hz Flickering Stimulation for Insomnia and Other Non-motor Symptoms in Patients With Parkinson's Disease","Inclusion Criteria:\n\n* Diagnosis of Parkinson's disease according to established clinical criteria (e.g., Movement Disorder Society criteria).\n* Age between 50 and 75 years.\n* Disease duration ≤ 10 years and Hoehn and Yahr stage ≤ 3 in the \"on\" state.\n* Clinically significant insomnia, defined as Parkinson's Disease Sleep Scale-2 (PDSS-2) total score ≥ 18 points and\u002For meeting diagnostic criteria for insomnia.\n* Stable antiparkinsonian medication regimen for at least 4 weeks prior to enrollment.\n* Able and willing to comply with study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Secondary insomnia primarily due to severe systemic diseases or major psychiatric disorders (e.g., psychosis, severe depression or anxiety) or substance abuse.\n* History of epilepsy, photosensitive seizures, photosensitive dermatitis, or other conditions in which flicker light stimulation is contraindicated.\n* Severe visual impairment or eye diseases that would interfere with light stimulation or safety assessment.\n* Unstable or severe medical conditions (e.g., uncontrolled cardiovascular, hepatic, renal, or endocrine disease) that, in the investigator's opinion, make participation unsafe.\n* Participation in another interventional clinical trial within the past 3 months.\n* Inability to complete study procedures or follow-up due to cognitive, physical, or social reasons.","50 Years","75 Years",{"count":108,"type":22},30,[25],"This randomized, single-blind, controlled clinical trial aims to evaluate the efficacy and safety of 40 Hz flicker light stimulation for insomnia in patients with Parkinson's disease (PD). Patients with PD and clinically significant insomnia will be randomly assigned in a 1:1 ratio to receive either 40 Hz flicker light or control light for 30 minutes every night at bedtime for 7 consecutive days, in addition to standard antiparkinsonian treatment.\n\nThe primary objective is to determine whether 40 Hz flicker light stimulation improves PD-related insomnia as measured by Parkinson's Disease Sleep Scale-2 (PDSS-2). Secondary objectives include evaluating changes in polysomnography-derived sleep parameters, subjective sleep quality, and other non-motor symptoms, as well as assessing the safety and tolerability of the intervention.\n\nThis registration specifically covers the Parkinson's disease insomnia cohort of a larger, previously approved multi-cohort protocol that also includes healthy volunteers and primary insomnia patients.",[112,113],"Parkinson Disease","Insomnia",[115,116,117,118,119],"Parkinson's disease","insomnia","sleep disorders","40 Hz flickering","gamma oscillation","2025-12-23",{"date":122,"type":38},"2026-01-07",{"date":124,"type":22},"2026-01-01",{"date":70,"type":22},{"name":43,"class":44},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":17,"minAge":105,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":147,"leadSponsor":148,"locationsCount":45},"100615948","remote-ischemic-conditioning-for-sleep-disturbances-and-other-non-motor-symptoms-in-parkinsons-disease-100615948","NCT07299240","Remote Ischemic Conditioning for Sleep Disturbances and Other Non-motor Symptoms in Parkinson's Disease","Remote Ischemic Conditioning for Sleep Disturbances and Other Non-motor Symptoms in Parkinson's Disease: a Randomized, Single-blind, Sham-controlled Clinical Study","Inclusion Criteria:\n\n* Diagnosis of Parkinson's disease according to the Movement Disorder Society (MDS) clinical diagnostic criteria.\n* Age between 50 and 70 years.\n* Disease duration ≤ 5 years.\n* Hoehn and Yahr stage I-III in the \"on\" state.\n* Presence of insomnia that meets the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria and clinically significant sleep complaints (for example, Parkinson's Disease Sleep Scale-2 \\[PDSS-2\\] total score ≥ 18 points).\n* On a stable regimen of antiparkinsonian medications for at least 4 weeks prior to enrollment, with no expected dose changes during the study period.\n* Able to understand the study procedures and provide written informed consent (or consent provided by a legally authorized representative when appropriate).\n\nExclusion Criteria:\n\n* Secondary insomnia due to other severe medical conditions (e.g., uncontrolled cardiopulmonary, hepatic, renal, or endocrine diseases).\n* Current psychotic symptoms or severe anxiety or depression (e.g., Hamilton Anxiety Scale score ≥ 14 or Hamilton Depression Scale score ≥ 17).\n* Other primary sleep disorders such as moderate-to-severe obstructive sleep apnea, restless legs syndrome, periodic limb movement disorder, or rapid eye movement sleep behavior disorder that require specific treatment.\n* History of significant cerebrovascular disease, brain tumor, central nervous system infection, or other neurological disorders that may interfere with sleep or study assessments.\n* Contraindications to remote ischemic conditioning (RIC), including severe peripheral arterial disease of the upper limbs, local soft tissue infection or damage at the cuff site, subclavian artery thrombosis, malignant hypertension, severe cardiac disease, active bleeding disorders, or other conditions judged unsafe by the investigator.\n* Contraindications to MRI or EEG examinations (e.g., pacemaker, severe claustrophobia, metallic implants incompatible with MRI).\n* Participation in another interventional clinical trial within the past 3 months.\n* Inability to comply with the study procedures or follow-up visits, as judged by the investigator.","70 Years",{"count":136,"type":22},48,[25],"This single-center, randomized, single-blind, sham-controlled clinical trial aims to evaluate whether remote ischemic conditioning (RIC) can improve sleep disturbances and other non-motor symptoms in patients with Parkinson's disease (PD). Forty-eight PD patients with insomnia will be randomly assigned in a 1:1 ratio to receive either active RIC (cuff inflation to high pressure) or sham RIC (cuff inflation to low pressure) for 7 consecutive days, in addition to their standard antiparkinsonian medications. Subjective sleep scales, sleep diaries, validated rating scales for motor and non-motor symptoms, and overnight polysomnography will be used to assess treatment effects at baseline, after the 7-day intervention, and during short-term follow-up. The study will also explore potential mechanisms of RIC by combining EEG, functional MRI, retinal optical coherence tomography, and blood biomarkers.",[140,113],"Parkinson Disease (PD)",[142,115,116,143],"remote ischemic conditioning","non-motor symptoms",{"date":145,"type":38},"2025-12-30",{"date":124,"type":22},{"date":70,"type":22},{"name":43,"class":44},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":157,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":161,"phases":4,"briefSummary":162,"conditions":163,"keywords":167,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":45},"100611958","multimodal-phenotyping-in-adolescent-inpatient-depression-an-observational-study-100611958","NCT07247344","Multimodal Phenotyping in Adolescent Inpatient Depression: An Observational Study","Digital Phenotyping and Multimodal Biomarker Discovery for Major Depressive Episodes in Adolescent Inpatients: A Prospective Cohort Study","MAPS-IO","Inclusion Criteria:\n\n* Between 10 and 20 years of age;\n* Diagnosis of major depressive disorder (MDD) or bipolar disorder (BD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Diagnosis is assessed using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) for participants aged ≥18 years, or the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K-SADS-PL) for participants aged \\\u003C18 years;\n* Current moderate to severe depressive episode, defined as Hamilton Depression Rating Scale (HAMD) score ≥17;\n* Participants and 1 or 2 parents (patients' age\\\u003C 18 years old) provide informed consent after the detailed description of the study.\n\nExclusion Criteria:\n\n* Prior treatment with repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), electroconvulsive therapy (ECT), or standard psychological therapy within 6 months prior to screening;\n* Comorbidity with other DSM-IV Axis I disorders or personality disorders;\n* Judged clinically to be at serious risk of suicide;\n* Diabetes mellitus, hypertension, vascular and infectious diseases and other major medical comorbidities;\n* Unstable medical conditions, e.g., severe asthma; Neurological disorders, e.g., history of head injury with loss of consciousness for ≥ five minutes, cerebrovascular diseases, brain tumors and neurodegenerative diseases;\n* Mental retardation or autism spectrum disorder;\n* Contraindications to MRI (e.g., severe claustrophobia, pacemakers, metal implants);\n* Current drug or alcohol abuse or dependence;\n* Pregnant or lactating females.","10 Years","20 Years",{"count":160,"type":22},1000,"OBSERVATIONAL","This cohort study involves the dynamic collection of clinical information from adolescent patients with major depressive episodes (including both major depressive disorder and bipolar disorder), encompassing serum parameters, physiological-behavioral signals, neuroimaging data, and neuropsychological scales. The study aims to summarize the comprehensive clinical characteristics of this population, identify new risk factors, and establish multivariate predictive models for treatment response, cognitive and emotional impairments. Furthermore, this research will thoroughly investigate the underlying neural mechanisms linking clinical manifestations and neuroimaging features in major depressive episodes.",[164,165,166],"Adolescent","Major Depressive Disorder (MDD","Bipolar Disorder (BD)",[168],"Major Depressive Episode","2025-11-23",{"date":171,"type":38},"2025-11-25",{"date":173,"type":38},"2025-03-01",{"date":175,"type":22},"2029-03",{"name":43,"class":44},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":17,"minAge":184,"maxAge":53,"enrollmentInfo":185,"targetDuration":4,"studyType":23,"phases":187,"briefSummary":188,"conditions":189,"keywords":194,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":45},"100611858","hd-tdcs-for-adolescent-bipolar-depression-targeting-s1-100611858","NCT07246044","HD-tDCS for Adolescent Bipolar Depression Targeting S1","High-Definition Transcranial Direct Current Stimulation (HD-tDCS) Targeting the Primary Somatosensory Cortex for Bipolar Depression in Adolescents: A Randomized Double-Blind Controlled Trial","Inclusion Criteria:\n\n* Between 12 and 18 years of age;\n* Participants fulfill the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnostic criteria for bipolar disorder (BD). Participants are assessed by the Structured Clinical Interview for DSM-IV for Axis I Disorders (SCID-I, patients' age ≥18 years old), or the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime version (K- SADS-PL, patients' age\\\u003C 18 years old);\n* A current moderate or severe depressive episode defined by HAMD≥17 and Young Mania Rating Scale (YMRS) \\\u003C12;\n* Participants receive a stable psychotropic medication regimen prior to randomization to the trial and are willing to remain on the stable regimen during the HD-tDCS treatment phase;\n* Participants and 1 or 2 parents (patients' age\\\u003C 18 years old) provide informed consent after the detailed description of the study.\n\nExclusion Criteria:\n\n* Prior rTMS or tDCS or electroconvulsive therapy (ECT) treatment or standard psychological therapy within 6 months prior to screening;\n* Comorbidity of other DSM-IV axis I disorders or personality disorders;\n* Judged clinically to be at serious suicidal risk;\n* Diabetes mellitus, hypertension, vascular and infectious diseases and other major medical comorbidities;\n* Unstable medical conditions, e.g., severe asthma;\n* Neurological disorders, e.g., history of head injury with loss of consciousness for ≥ five minutes, cerebrovascular diseases, brain tumors and neurodegenerative diseases;\n* Mental retardation or autism spectrum disorder;\n* Contraindications to MRI (e.g., severe claustrophobia, pacemakers, metal implants);\n* Contraindications to tDCS (e.g., metal in head, history of seizure, EEG test suggesting high risk of seizure, known brain lesion);\n* Current drug\u002Falcohol abuse or dependence;\n* Pregnant or lactating female.","12 Years",{"count":186,"type":22},100,[25],"This randomized, double-blind, sham-controlled clinical trial aims to evaluate the efficacy and underlying biological mechanisms of HD-tDCS targeting the primary somatosensory cortex in adolescents with bipolar depression. Participants will be randomly assigned to receive either active HD-tDCS or sham stimulation, in addition to routine clinical care. Biological data, including neuroimaging, blood biomarkers, voice and facial features, Photoplethysmography (PPG), Electroencephalography (EEG), and behavioral data, will be collected to explore potential predictors of treatment response.",[164,190,191,192,193],"Bipolar Depression","tDCS","Primary Somatosensory Cortex","Bipolar Disorder Depression",[195,196,197,198],"primary somatosensory cortex","adolescent","bipolar depression","high-definition transcranial direct current stimulation","2025-11-17",{"date":201,"type":38},"2025-11-24",{"date":203,"type":38},"2025-09-16",{"date":205,"type":22},"2027-12-31",{"name":43,"class":44},{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":19,"enrollmentInfo":214,"targetDuration":4,"studyType":23,"phases":216,"briefSummary":218,"conditions":219,"keywords":221,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":45},"100598726","phase-4-efficacy-and-functional-recovery-after-switching-from-paliperidone-palmitate-injection-to-oral-antipsychotics-in-schizophrenia-100598726","NCT07075237","Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia","A Study on the Efficacy and Functional Recovery of Switching From Oral Antipsychotics to Paliperidone Palmitate Injection in the Treatment of Schizophrenia","Inclusion Criteria:\n\n1. Outpatients or inpatients meeting DSM-5 diagnostic criteria forschizophrenia;\n2. Aged 18-65 years (inclusive), regardless of gender;\n3. Currently receiving first- or second-generation oral antipsychotics (excluding clozapine) with stable condition as assessed by the investigator, and PANSS total score ≤80 at screening and baseline;\n4. Signed informed consent by the patient and\u002For guardian;\n\nExclusion Criteria:\n\n1. Comorbid psychiatric diagnoses other than schizophrenia;\n2. Severe physical diseases, intellectual disability, organic brain disorders, or mental disorders due to physical illnesses;\n3. QTc interval \\>450 ms (male) or \\>460 ms (female);\n4. History of psychoactive substance abuse (excluding tobacco) within the past 12 months, or significant suicidal\u002Fviolent tendencies;\n5. Current or history of tardive dyskinesia (TD), neuroleptic malignant syndrome (NMS), or severe extrapyramidal symptoms (EPS);\n6. Treatment-resistant schizophrenia (failure of ≥2 adequate antipsychotic regimens of different compounds);\n7. Hypersensitivity or inefficacy to risperidone or paliperidone; 8. Pregnancy, lactation, planned pregnancy, or failure to use effective contraception during the study;\n\n9\\. Other conditions deemed unsuitable by the investigator. \\|",{"count":215,"type":22},120,[217],"PHASE4","To evaluate the efficacy of Paliperidone Palmitate Injection in replacing oral antipsychotics for the treatment of schizophrenia and its impact on social function",[220],"Schizophrenia",[220,222,223,224],"Paliperidone Palmitate","Oral antipsychotics","Social function|","2025-09-24",{"date":227,"type":38},"2025-09-29",{"date":229,"type":22},"2025-10",{"date":231,"type":22},"2027-03",{"name":43,"class":44},{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":106,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":243,"conditions":244,"keywords":250,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":4},"100575000","ivonescimab-combined-with-chemotherapy-for-the-treatment-of-leptomeningeal-metastases-failed-to-egfr-tkis-100575000","NCT06766591","Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs","Ivonescimab Combined With Chemotherapy for EGFR Mutant NSCLC With Leptomeningeal Metastasis After EGFR TKIs Resistance: A Multicenter Observational Study.","Inclusion Criteria:\n\n* Age range: 18-75y\n* EGFR mutation NSCLC\n* LM was diagnosed through head enhanced MRI or (and) CSF cytology\n* EGFR activation mutations were positive\n* Patients who have failed to first or second-generation EGFR-TKI treatment，without T790M mutation; or failed to third-generation EGFR-TKI treatment\n* Hematological, coagulation, renal and liver function is sufficient\n* Women of childbearing age must undergo a pregnancy test and the result must be negative\n\nExclusion Criteria:\n\n* Patients with squamous cell carcinoma, large cell carcinoma, mixed cell lung cancer\n* The patient has other driver genes that can be treated with targeted drugs\n* Subjects who have previously received immunotherapy with a discontinuation time of less than 3 months\n* Received EGFR-TKI treatment within one week prior to the first administration\n* Received non-specific immunomodulatory therapy\n* Clinical manifestations of neurological failure\n* Non malignant neurological disorders\n* Radiotherapy for the chest and whole brain should be completed within 4 weeks before enrollment\n* Tumor surrounded important blood vessels or had obvious necrosis or cavities\n* Tumor has invaded important surrounding organs and blood vessels\n* History of severe bleeding tendency or coagulation dysfunction\n* The risk of developing esophagotracheal fistula or esophageal pleural fistula",{"count":241,"type":22},36,[25],"Research objective Main purpose Exploring the real-world effectiveness of Ivonescimab combined with chemotherapy for EGFR mutant NSCLC with leptomeningeal metastasis after EGFR-TKIs resistance. Outcome measure: Real world intracranial disease-free survival time (iPFS).\n\nSecondary purpose Federation patterns: describing different treatment modes in the real world; Outcome measures: Combination chemotherapy regimen and duration of chemotherapy.\n\nEfficacy: Further explore the effectiveness of Ivonescimab combined with chemotherapy for EGFR mutant NSCLC with leptomeningeal metastasis failed with EGFR-TKI treatment; Outcome measures: Objective response rate (LM-ORR), duration of intracranial response (iDoR), overall progression free survival (PFS), overall survival (OS), improvement in neurological function, CSF response rate based on CSF cytology.\n\nSafety: Explore the safety of Ivonescimab combined with chemotherapy for NSCLC patients with leptomeningeal metastases who have failed EGFR-TKI treatment; Outcome measures: incidence of adverse events (TEAEs), laboratory test outliers, and serious adverse events (SAEs).\n\nResearch endpoint Primary endpoint\n\n* iPFS (intracranial progression free survival). Secondary endpoint\n* Efficacy: leptomeningeal ORR (LM-ORR), intracranial duration of response (iDoR), overall progression free survival (PFS), overall survival (OS), improvement in neurological function, and CSF response rate based on CSF cytology;\n* Safety: Determine the incidence and severity of adverse events (AE) and serious adverse events (SAE) according to NCI-CTCAE5.0 standards; Changes in vital signs, laboratory abnormalities, and quality of life scores.\n\nExploratory endpoint: efficacy related biomarkers",[245,246,247,248,249],"NSCLC","Chemotherapy","Leptomeningeal Metastases","EGFR-TKI","AK112",[251,245,252,248,253,254],"Ivonescimab","leptomeningeal metastases","VEGF","PD-1\u002FVEGF bispecific antibody","2025-01-05",{"date":257,"type":38},"2025-01-09",{"date":259,"type":22},"2025-01-01",{"date":261,"type":22},"2025-10-31",{"name":43,"class":44},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":270,"sex":17,"minAge":271,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":275,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":45},"100489086","effect-of-music-therapy-in-mental-subhealth-emtms-100489086","NCT05648539","Effect of Music Therapy in Mental Subhealth (EMTMS)","Effect of Music Therapy in Mental Subhealth: A Randomized Controlled Trial","Inclusion Criteria:\n\nA total of \\> 5 on PHQ-9 or a total of \\> 5 on GAD-7\n\nExclusion Criteria:\n\nAcute suicidal thoughts, With a severe or potentially confounding psychiatric disorder (e.g. psychosis, substance misuse).",true,"16 Years","35 Years",{"count":274,"type":22},150,[25],"Mental health is increasingly at the forefront of concerns, especially since the start of COVID-19 pandemic. However, not all individuals under mental subhealth need pharmaceutical treatment. Music Therapy (MT) can make peoples gradually relax via relaxing and soothing music, and regulate individual psychological emotions through the influence of music on individuals' cerebral cortex, hypothalamus and limbic system, further improve the mood of daily tension and anxiety.\n\nThis study adopted randomized clinical trials design, with two groups of MT group and Waiting group both under mental subhealth. The MT group received music therapy and routine activities, while the Waiting group received music therapy after the therapy of MT group. Data collections were performed by trained, certified, and qualified personnel. The study aims to provide that MT is an effective intervention way to alleviate the mental subhealth state in the future.",[278],"Depression, Anxiety",[62,278,280],"Acoustic features","2023-04-13",{"date":283,"type":38},"2023-04-18",{"date":285,"type":22},"2023-04-19",{"date":287,"type":22},"2027-10-31",{"name":43,"class":44},""]